MBG 453

Drug Profile

MBG 453

Alternative Names: MBG453

Latest Information Update: 21 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies; Vaccines
  • Mechanism of Action HAVCR2 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 30 Jun 2017 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Australia (unspecified route) (NCT03066648)
  • 30 Jun 2017 Phase-I clinical trials in Myelodysplastic syndromes (Combination therapy) in Australia (unspecified route) (NCT03066648)
  • 03 Mar 2017 Novartis Pharmaceuticals plans a phase I trial (Combination therapy, Refractory metastatic disease) for Acute Myeloid Leukemia and Myelodysplastic Syndrome in USA (NCT03066648)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top